Business Context and Reporting Period
Company: CopyTele, Inc. (Note: Metadata referenced Anixa Biosciences, but filing text identifies CopyTele, Inc.)
Reporting Period: Quarterly period ended July 31, 1995 (Nine months ended July 31, 1995).
Status: Development Stage Enterprise.
Operations: The company has generated no revenue since inception (November 5, 1982). Principal activities focus on a joint venture in China (Shanghai CopyTele Electronics Co., Ltd.) for the development of telecommunications products utilizing flat panel technology.
Key Financial Metrics
| Metric | Nine Months Ended July 31, 1995 | Nine Months Ended July 31, 1994 |
|---|---|---|
| Sales/Revenue | $0 | $0 |
| Net Loss | ($2,074,941) | ($2,770,542) |
| Net Loss Per Share | ($0.08) | ($0.11) |
| Operating Cash Flow | ($1,968,580) | ($2,841,318) |
| Financing Cash Flow | $4,845,236 | $1,597,825 |
| Cash and Equivalents (End of Period) | $8,720,050 | $7,031,620 |
| Total Assets | $9,414,379 | $6,614,332 |
| Accumulated Deficit | ($22,396,012) | ($20,321,071) |
| Debt | None reported | None reported |
Material Changes vs. Prior Period
- Expense Reduction: Selling, general, and administrative expenses decreased to $2,314,749 for the nine months ended July 31, 1995, compared to $2,929,113 in the prior year. This was primarily due to reduced engineering supplies expenditures.
- Interest Income Increase: Interest income rose to $239,808 from $158,571 in the prior year, driven by higher interest rates on investments.
- Joint Venture Investment: The company made a $367,500 investment in its Chinese joint venture subsidiary during the period, recorded under the equity method.
- Capital Raising: Net cash provided by financing activities increased significantly to $4.8 million, primarily from the exercise of stock options and warrants.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current funds are sufficient to maintain development efforts and complete initial capital contributions to the joint venture (approx. $850,000 remaining) through the fourth quarter of fiscal 1997.
- Future Funding Needs: The company anticipates requiring additional funds to continue R&D and participate further in the joint venture. There is no assurance such funds will be available on favorable terms.
- NASDAQ Compliance: The company must maintain $4 million in net tangible assets to retain its NASDAQ-NMS listing. Management anticipates seeking additional funding to satisfy this requirement.
- Revenue Risk: There is no assurance that marketable products will be developed or that the company will generate future revenue. Products could be rendered obsolete by competitors.
- Executive Compensation: The Chairman, President, and several senior personnel have waived salaries and pension benefits for an undetermined period, a factor relied upon in liquidity projections.
Investor Verification Checklist
- Revenue Timeline: Verify if there are any new developments regarding the commercialization of flat panel technology or the joint venture that could generate revenue before fiscal 1997.
- Capital Requirements: Assess the likelihood of raising additional capital to meet the $4 million NASDAQ net tangible asset requirement and fund ongoing R&D.
- Joint Venture Viability: Review the progress of the Shanghai joint venture and the status of the remaining $850,000 capital contribution.
- Executive Waivers: Confirm the continued status of salary waivers by key executives, as the liquidity runway depends on this cost-saving measure.
- Stock Dilution: Monitor the exercise of the 4.2 million outstanding stock options and 481,983 warrants, which could significantly dilute existing shareholders.